Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects

NCT04818229 is registered in ClinicalTrials.gov with Connect Biopharma Australia Pty Ltd as lead sponsor.

NCT NCT04818229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects
Lead sponsor
Connect Biopharma Australia Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2021
Completion date
March 30, 2022
Enrollment
112 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases